-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Primary aldosteronism (PA) due to excessive secretion of adrenal aldosterone, resulting in vivo sodium retention, potassium row, increased blood volume, the renin - vascular angiotensin system activity inhibition, clinical manifestations of hypertension associated with hypokalemia , Accounting for about 10% of clinically hypertensive patients.
Vascular medsci.
Recently, researchers investigated the evaluation and treatment rate of primary aldosteronism in medical institutions in Canada.
Recently, researchers investigated the evaluation and treatment rate of primary aldosteronism in medical institutions in Canada.
This study was conducted in Alberta, Canada.
Screening
A total of 1.
Only 7941 people (0.
PA screening rate and positive rate in hypertensive population
The study found that among adults with hypertension in Alberta, Canada, less than 1% of patients with primary aldosteronism are expected to be formally diagnosed and treated.
Only less than 1% of patients with primary aldosteronism are expected to be formally diagnosed and treated.
Original source:
Yuan-yuan Liu et al.
com/journals/jamasurgery/article-abstract/2777912" target="_blank" rel="noopener">Outcomes of a Specialized Clinic on Rates of Investigation and Treatment of Primary Aldosteronism.
JAMA
Leave a message here